Essex Bio-Technology Limited disclosed in its Monthly Return for Equity Issuer that a series of share repurchases in August 2026 reduced its outstanding ordinary shares by 0.53 million to 565.12 million as at 31 August 2026. Treasury shares simultaneously rose by the same amount to 1.88 million, leaving total issued shares unchanged at 567.01 million.

Key figures for August 2026 • Authorised share capital remained flat at 1.00 billion ordinary shares with a par value of HKD 0.10, representing HKD 100.00 million in authorised capital. • Issued shares (excluding treasury) fell from 565.65 million to 565.12 million, a 0.09% month-on-month reduction. • Treasury shares increased from 1.36 million to 1.88 million. • The company confirmed compliance with the Main Board’s 25% minimum public-float requirement.

Repurchase activity Between 6 August and 24 August 2026, Essex Bio-Tech executed five on-market buy-backs: – 191,000 shares at HKD 2.3705 on 6 August – 259,000 shares at HKD 2.3718 on 7 August – 20,000 shares at HKD 2.3000 on 19 August – 18,000 shares at HKD 2.3000 on 21 August – 40,000 shares at HKD 2.2650 on 24 August

The transactions totalled 528,000 shares repurchased for an estimated HKD 1.25 million, implying a weighted-average cost of approximately HKD 2.36 per share.

Equity incentive capacity No share options were exercised during the month. The 2023 Share Option Scheme retains capacity for up to 57.06 million ordinary shares to be issued or transferred from treasury.

Capital structure snapshot (31 August 2026) • Total authorised share capital: HKD 100.00 million • Total issued shares: 567.01 million • Issued shares (ex-treasury): 565.12 million • Treasury shares: 1.88 million

The monthly disclosure was submitted by Director Mr. Fang Haizhou on 1 September 2026.